Open Orphan’s hVIVO launches its Disease in Motion platform

Open Orphan plc (LON:ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation and world leader in vaccine and antiviral testing using human challenge clinical trials, has announced that hVIVO, a subsidiary of Open Orphan, has officially launched its Disease in Motion® platform. This unique data-focused platform includes clinical, immunological, virological and digital (wearable) biomarkers. The Disease in Motion platform has multiple infectious disease applications that are applicable to a wide variety of end users including big tech, wearables, pharma and biotech companies.

hVIVO has been at the forefront of running human challenge studies for more than 20 years and has built up one of the most comprehensive, multi-parametric bio and databanks ever created for infectious diseases. This dataset from the Disease in Motion platform is continuously gathered throughout the onset, progression and resolution of an infection which is enabled by hVIVO’s challenge study model. The Company is committed to volunteer patient data privacy and data is only collected from fully consented volunteers in accordance with all relevant privacy guidelines. 

For more information on the platform, please visit www.hvivo.com/DiseaseInMotion  

Cathal Friel, Executive Chairman said: “The Disease in Motion platform includes data from cutting edge wearables that are applicable to a wide variety of end users including big tech, wearables, pharma and biotech companies. As volunteers remain under close observation prior to viral challenge, during disease progression and until resolution, data is captured across the full time-course of the infection, yielding possible insights into the body’s response to infection. The Disease in Motion platform currently spans several conditions with plans to expand this going forward.  

As a recognised global leader in supporting the development of therapeutics and vaccines, hVIVO and our team of virological, clinical and regulatory experts are actively in discussion with potential partners to help address the next set of challenges facing humanity.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
Open Orphan Plc

More articles like this

Open Orphan Plc

Open Orphan appoints Yamin ‘Mo’ Khan as Chief Executive Officer

Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announced today the appointment of Yamin ‘Mo’ Khan as Chief Executive Officer

Open Orphan Plc

Potential RSV vaccine achieves regulatory step in US

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for a vaccine candidate for respiratory syncytial virus (RSV). Bavarian Nordic’s MVA-BN RSV was granted the designation, which is designed to expedite the development

Open Orphan Plc

Open Orphan FDA Breakthrough Designation for Big Pharma RSV candidate

Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, noted today the announcement dated 14 February 2022 from Bavarian Nordic A/S (OMX: BAVA), reporting

Open Orphan Plc

The Drug development plan – Your roadmap to success

Each journey begins at a starting point, and we believe that few journeys are as exciting as developing a drug. In order to succeed and reach your destination, you need a solid roadmap, the drug development

Open Orphan Plc

Open Orphan launch STRiVE project a remarkable success

Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that hVIVO, a subsidiary of Open Orphan plc, has recently launched

Open Orphan Plc

What is malaria?

Malaria is often quoted as the most common disease in all human history. With the earliest recorded cases are estimated to have been around 10,000 years ago, when a small plasmodium parasite made a jump across

Open Orphan Plc

Omicron and Long COVID: What we know so far

As the Omicron variant of the coronavirus continues to sweep across the United States, another important question has emerged for scientists worldwide: Will more transmission equal more long COVID cases? The rate of hospitalization has also

Open Orphan Plc

Pharmacokinetics Course

Pharmacokinetics (PK) is generally referred to as ‘what the body does to the drug’ versus ‘what the drug does to the body’ (pharmacodynamics [PD]). Pharmacokinetics describes the fate, or time course, of an administered drug within

Open Orphan Plc

Open Orphan launch new malaria human challenge

Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials announces that further to the announcement on 9 August 2021, hVIVO, a subsidiary

Open Orphan Plc

RSV vaccines & treatments

The Challenge Respiratory syncytial virus (RSV) is the single most important cause of lower respiratory tract infection (LRTI) in infants and young children worldwide and can cause LRTI in elderly and immunocompromised patients; it is associated

Open Orphan Plc

FluCamp 2021 Year in Review

Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO